SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Changes in creatinine and estimated glomerular filtration rate during the first 12-month period of pre-exposure prophylaxis among PrEP-30 clients at the Thai Red Cross anonymous clinic- Piyanuch TuntikulView Slideset
YHYi-Chia HuangMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Feasibility and outcome of rapid initiation of antiretroviral treatment among newly-diagnosed HIV-positive patients at a tertiary center in Taiwan- Yi-Chia HuangView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan- Wang-Da LiuView Slideset
RRReena RajasuriarMPharm, PhDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Addressing long-term complications to improve health outcomes in HIV- Reena Rajasuriar, MPharm, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Social media platforms for LGBT inclusion- Laurindo GarciaView Slideset
KRKiat RuxrungthamMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Improving tolerability by optimizing ART- Kiat Ruxrungtham, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Optimal timing of antiretroviral therapy for HIV-infected patients with cryptococcal meningitis: A systematic review and meta-analysis- Yaokai ChenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Replicating the success: Using an HIV model of peer driven intervention (PDI+) to increase TB new case detection in Cambodia- Kolab ChhimView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Routine versus targeted viral load strategy among patients starting ART in Hanoi, Vietnam- Todd PollackView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Assessing the efficacy of Lopinavir /ritonavir based preferred and alternative second-line regimens on HIV-infected patients : a meta-analysis as a key evidence support for WHO recommendations- Yaokai ChenView Slideset
YSYinzhong ShenMDSlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018DTG versus LPV/r in second line (DAWNING): outcomes by WHO-recommended NRTI backbone- Yinzhong ShenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAPACC 2018Cost-effectiveness of Dolutegravir in HIV-1 treatment-naïve patients in China- Yogesh PunekarView Slideset
